Naxitamab for sarcoma, ewing

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Aug 2023: Trial registered, NCT05968768
  2. 24 Oct 2023: Trial started, NCT05968768

The trials

NCT05968768: To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

State
Under way
Phase
Phase 2
People
24 planned
Started
24 Oct 2023
Primary completion
1 May 2027
Arms
Experimental - Naxitamab Arm
Results
None posted
  1. 1 Aug 2023: Trial registered
  2. 24 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.